May Nesfatin-1 be a biomarker in Acute mesenteric ischemia?

Abstract

Objective: to investigate the diagnostic value of nesfatin-1 in cases of intestinal ischemia and ischemia/reperfusion. Study Design: An experimental study. Place and Duration of Study: the Experimental Animals Laboratory of Bezmialem University, in June 2018. Methodology: twenty-one healthy male Sprague Dawley rats were randomly divided into three groups of 7 rats each. In group 1: 1-hour intestinal ischemia followed by 5-hour reperfusion was performed. In group 2: rats were subjected to 6-hour intestinal ischemia. In group 3: rats underwent laparotomy and closure without performing any further procedure. Changes in leukocyte count, amylase, blood sugar, LDH, SGOT, CRP, and nesfatin-1 levels were determined. For histopathological examination, a small intestinal sample was taken and preserved in 10% formaldehyde. Results: nesfatin-1 value in group 2 was significantly higher than that in group 1 and group 3 (p=0.005, and p <0.001 respectively). Nesfatin-1 value in group 1 was significantly higher than that in group 3. A significant (r = 0.864/p <0.001) positive correlation was observed between nesfatin-1 value and pathology score. The pathology score of group 2 was significantly higher than that of group 1 and group 3 (p <0.001). Conclusion: serum nesfatin-1 can be a biomarker in acute mesenteric ischemia.